A Phase Ia, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single-ascending doses of RO7303509 in healthy volunteers
Latest Information Update: 28 Apr 2024
At a glance
- Drugs RO 7303509 (Primary) ; RO 7303509 (Primary)
- Indications Inflammation
- Focus Adverse reactions
- Sponsors Genentech
- 03 Jun 2023 Results assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7303509 in healthy volunteers presented at the 24th Annual Congress of the European League Against Rheumatism
- 22 Jul 2022 Planned number of patients changed from 56 to 57.
- 03 Jun 2022 Status changed from active, no longer recruiting to completed.